CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.3% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade Vir Biotechnology VIR

Sell
 Buy

VirBiotechnology live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2026 Feb 24, 07:16

Vir Biotech Soars On Global Collaboration With Astellas, Encouraging Prostate Cancer Drug Data

Vir Biotechnology Inc
Webhose 2026 Feb 24, 06:19

Vir Biotechnology Shares Jump Over 50% After Positive Phase 1 VIR-5500 Prostate Cancer Data

Vir Biotechnology Inc
Webhose 2026 Feb 24, 05:02

Vir Biotechnology Inc (VIR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ...

Vir Biotechnology Inc
Webhose 2026 Feb 24, 01:08

Vir Biotechnology (NASDAQ:VIR) Releases Earnings Results, Beats Expectations By $0.11 EPS

Vir Biotechnology Inc
Webhose 2026 Feb 24, 00:06

Vir Biotechnology Q4 Earnings Call Highlights - Stock Observer

Vir Biotechnology Inc
Webhose 2026 Feb 24, 00:00

Japan's Astellas announces $1.37 B deal with Vir Biotechnology to develop T-Cell therapies for prostate cancer

Vir Biotechnology Inc
Webhose 2026 Feb 23, 22:14

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Morningstar

Vir Biotechnology Inc
Webhose 2026 Feb 23, 22:13

Astellas and Vir Biotechnology Announce Global Strategic Col

Vir Biotechnology Inc
Webhose 2026 Feb 23, 22:07

Astellas collaborates with Vir to develop its experimental prostate cancer drug

Vir Biotechnology Inc
Webhose 2026 Feb 23, 22:02

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer | Morningstar

Vir Biotechnology Inc
Webhose 2026 Feb 21, 13:18

Vir Biotechnology (NASDAQ:VIR) CAO Sells $11,918.70 in Stock

Vir Biotechnology Inc
Webhose 2026 Feb 20, 09:00

Aberdeen Group plc Purchases 519,374 Shares of Vir Biotechnology, Inc. $VIR

Vir Biotechnology Inc
Webhose 2026 Feb 18, 20:59

Vir Biotechnology (NASDAQ:VIR) CAO Brent Sabatini Sells 1,530 Shares

Vir Biotechnology Inc
Webhose 2026 Feb 17, 08:13

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by Analysts

Vir Biotechnology Inc
Webhose 2026 Feb 16, 08:40

Vir Biotechnology (VIR) Projected to Post Earnings on Monday

Vir Biotechnology Inc
Webhose 2026 Feb 09, 13:12

Needham & Company LLC Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR) - Markets Daily

Vir Biotechnology Inc
Webhose 2026 Feb 09, 08:12

Vir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLC - Stock Observer

Vir Biotechnology Inc
Webhose 2026 Feb 03, 19:53

Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares

Vir Biotechnology Inc
Webhose 2026 Feb 02, 11:11

Did Vir's Advancing Hepatitis D Combo Program Just Shift Vir Biotechnology's (VIR) Investment Narrative? - Simply Wall St News

Vir Biotechnology Inc
Webhose 2026 Jan 29, 22:31

Chronic Hepatitis D Market Poised for Significant Growth During the Forecast Period (2025-2034) as Emerging Therapies Drive Optimism | DelveInsight

Vir Biotechnology Inc
Webhose 2026 Jan 26, 00:27

Vir Biotechnology (VIR) Is Up 24.8% After Strong SOLSTICE Combo Data In Hepatitis Delta Trial - Has The Bull Case Changed?

Vir Biotechnology Inc

VirBiotechnology news

Latest news

Show more

Info

Spread

0.07

Spread (%)

0.7423 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Wednesday

14:31 - 20:59

Monday

14:31-20:59

Tuesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1033698880

Shares Outstanding

139125032

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-3.62

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

Latest Education Articles

Show more
Trustpilot